Clinical Trial Update: Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated vandetanib for ovarian, fallopian tube, and primary peritoneal cancers; the study was terminated and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2012-06-26